


Tasimelteon 02/20

ALTERNATE NAMES: N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; Hetlioz; BMS 214778;

VEC-162; MA 1; (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

CATALOG #: B2985-5 5 mg B2985-25 25 mg

STRUCTURE:



MOLECULAR WEIGHT: 245.32

CAS NUMBER: 609799-22-6

APPEARANCE: White to Off-White powder

PURITY: 95%

SOLUBILITY: ~2 mg/ml in DMSO

DESCRIPTION: Tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA). It is used to treat non-24-hour sleep-

wake disorder. The K_i values for binding affinity at melatonin receptors MT1 and MT2 receptor are 0.304 and 0.069 nM respectively in CHO–K1 cells. It shows greater affinity for the MT2 receptor which is believed to mediate circadian rhythm phase-shifting. It induces a potent, concentration-dependent inhibition of forskolin-stimulated cAMP accumulation in NIH-3T3 cells stably expressing human MT1

and MT2 receptors with EC_{50} values of 0.74 nM and 0.1 nM repectively.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

REFERENCE: Lavedan, C., Forsberg, M., and Gentile, A.J. Tasimelteon: A selective and unique receptor binding

profile. Neuropharmacology 91, 142-147 (2015).

RELATED PRODUCTS:

PF-670462 (Cat. No. B2271) Melatonin ELISA Kit (Cat. No. E4630) GSK-4112 (Cat. No. 9663) Melatonin (Cat. No. 2488) CLOCK Antibody (Cat. No. 3896)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.